...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Pronounced tumour regression after radiotherapy is associated with negative/weak glucose transporter-1 expression in rectal cancer.
【24h】

Pronounced tumour regression after radiotherapy is associated with negative/weak glucose transporter-1 expression in rectal cancer.

机译：放射治疗后明显的肿瘤消退与直肠癌中负/弱葡萄糖转运蛋白-1表达相关。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The aim of this study was to assess glucose transporter-1 (GLUT-1) expression as a predictor of disease outcome in rectal cancer treated by preoperative radio- or chemoradiotherapy. PATIENTS AND METHODS: Operative samples from 175 rectal cancer patients and 78 preoperative biopsies were analysed for GLUT-1 expression using immunohistochemistry. Forty-six patients received long-course radiotherapy, with/without chemotherapy and tumour regression grade was analysed in these specimens. RESULTS: Negative GLUT-1 expression was seen in 25/78 (32%) of the preoperative biopsies and in 38/78 (49%) of the operative samples. There was no significant correlation of GLUT-1 with common clinicopathological factors. A trend towards longer disease-free survival (DFS) for the long-course radiotherapy group patients was seen with negative/weak GLUT-1 staining intensity (p=0.066) and excellent tumour regression grade (p=0.068) in operative samples. Disease-free survival (p=0.068) and disease-specific survival (p=0.024) of the patients with excellent tumour regression were longer than among the patients with moderate or less regression. CONCLUSION: A trend towards longer DFS among patients in favour of negative/weak GLUT-1 staining in the operative samples after long-course radiotherapy is demonstrated.
机译：这项研究的目的是评估葡萄糖转运蛋白1（GLUT-1）的表达，作为术前放疗或放化疗所治疗的直肠癌疾病预后的指标。患者与方法：使用免疫组织化学分析了175例直肠癌患者和78例术前活检的手术样本中GLUT-1的表达。四十六例患者接受了长程放疗，有无化疗，并对这些标本进行了肿瘤消退分级分析。结果：术前活检的25/78（32％）和术中样本的38/78（49％）GLUT-1表达阴性。 GLUT-1与常见的临床病理因素无显着相关性。对于长期放疗组患者，手术样本中GLUT-1染色强度为阴性/弱（p = 0.066）和优异的肿瘤消退等级（p = 0.068），这表明其趋于无病生存期更长（DFS）。肿瘤消退良好的患者的无病生存期（p = 0.068）和疾病特异性生存期（p = 0.024）要比中度或较少消退的患者更长。结论：证实了长期放疗后手术样本中患者DFS延长的趋势，有利于阴性/弱GLUT-1染色。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号